Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 10;7(19):5713-5716.
doi: 10.1182/bloodadvances.2022009066.

The race is on: bispecifics vs CAR T cells in B-cell lymphoma

Ashwath Gurumurthi  1 , Jason Westin  1 , Marion Subklewe  2   3
Affiliations

The race is on: bispecifics vs CAR T cells in B-cell lymphoma

Ashwath Gurumurthi et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: M.S. receives industry research support from Amgen, Bristol Myers Squibb/Celgene, Gilead, Janssen, Miltenyi Biotec, MorphoSys, Novartis, Roche, Seattle Genetics, and Takeda; serves as a consultant/adviser to AvenCell, CDR-Life, Ichnos Sciences, Incyte Biosciences, Janssen, Molecular Partners, and Takeda; and serves on the speakers’ bureau at Amgen, AstraZeneca, Bristol Myers Squibb/Celgene, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, Roche, and Takeda. J.W. receives industry research support from Kite/Gilead, Bristol Myers Squibb, Novartis, Genentech/Roche, AstraZeneca, Janssen, ADC Therapeutics, MorphoSys/Incyte, and Kymera, and serves as a consultant/adviser to Kite/Gilead, Bristol Myers Squibb, Novartis, Genentech/Roche, AstraZeneca, Janssen, ADC Therapeutics, MorphoSys/Incyte, AbbVie, Seagen, MonteRosa, Umoja, and Iksuda. A.G. serves as an adviser to Kite Pharma.

References

    1. Subklewe M. BiTEs better than CAR T cells. Blood Adv. 2021;5(2):607–612. - PMC - PubMed
    1. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42. - PMC - PubMed
    1. Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403–1415. - PubMed
    1. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852. - PubMed
    1. Westin JR, Kersten MJ, Salles G, et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021;96(10):1295–1312. - PMC - PubMed

Publication types